These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 20298134

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E.
    Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?
    Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos DG.
    Int Urol Nephrol; 2006 Apr; 38(3-4):739-43. PubMed ID: 17160632
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.
    Górriz JL, Molina P, Bover J, Barril G, Martín-de Francisco AL, Caravaca F, Hervás J, Piñera C, Escudero V, Molinero LM, en nombre de los investigadores del estudio OSERCE.
    Nefrologia; 2013 Jan 18; 33(1):46-60. PubMed ID: 23364626
    [Abstract] [Full Text] [Related]

  • 8. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ, Shaheen FA.
    Saudi J Kidney Dis Transpl; 2010 Jan 18; 21(1):93-101. PubMed ID: 20061700
    [Abstract] [Full Text] [Related]

  • 9. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels.
    Haffner D, Leifheit-Nestler M.
    Pediatr Nephrol; 2020 Mar 18; 35(3):485-491. PubMed ID: 31823044
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Establishment of reference values in a healthy population and interpretation of serum PTH concentrations in hemodialyzed patients according to the KDIGO Guidelines using the Lumipulse® G whole PTH (3rd generation) assay.
    Cavalier E, Salsé M, Dupuy AM, Bargnoux AS, Watar F, Souberbielle JC, Delanaye P, Cristol JP.
    Clin Biochem; 2018 Apr 18; 54():119-122. PubMed ID: 29501417
    [Abstract] [Full Text] [Related]

  • 12. Can calcium, phosphate, calcium phosphate product and intact parathyroid hormone levels be appropriately controlled in dialysis patients?
    Deger SM, Mutluay R, Derici U, Mandiralioglu F, Arinsoy T, Sindel S.
    Med Princ Pract; 2011 Apr 18; 20(1):85-9. PubMed ID: 21160221
    [Abstract] [Full Text] [Related]

  • 13. [Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients].
    Akiba T.
    Clin Calcium; 2009 Apr 18; 19(4):537-44. PubMed ID: 19329833
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Adherence to Kidney Disease: Improving Global Outcomes Mineral and Bone Guidelines for Monitoring Biochemical Parameters.
    Roetker NS, Peng Y, Ashfaq A, Gilbertson DT, Wetmore JB.
    Am J Nephrol; 2019 Apr 18; 49(3):225-232. PubMed ID: 30820015
    [Abstract] [Full Text] [Related]

  • 16. Influence of four different PTH methods on the classification of chronic kidney disease patients according to the new KDIGO guideline.
    Ten BE, Van Veen MC, Vervloet MG, Fischer JC, Koopman MG, Van Dam B.
    Clin Lab; 2012 Apr 18; 58(7-8):719-24. PubMed ID: 22997972
    [Abstract] [Full Text] [Related]

  • 17. Short- and long-term impact of subtotal parathyroidectomy on the achievement of bone and mineral parameters recommended by clinical practice guidelines in dialysis patients: a 12-year single-center experience.
    Tsai WC, Peng YS, Yang JY, Hsu SP, Wu HY, Pai MF, Chang JF, Chen HY.
    Blood Purif; 2013 Apr 18; 36(2):116-21. PubMed ID: 24217122
    [Abstract] [Full Text] [Related]

  • 18. Association between Hemodialysis Patient Outcomes and Compliance with KDOQI and KDIGO Targets for Mineral and Bone Metabolism.
    Djukanović L, Dimković N, Marinković J, Djurić Ž, Knežević V, Lazarević T, Ljubenović S, Marković R, Rabrenović V.
    Nephron; 2016 Apr 18; 132(3):168-74. PubMed ID: 26914677
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis.
    Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, D'Haese PC, Drüeke TB, Du H, Manley T, Rojas E, Moe SM.
    Am J Kidney Dis; 2016 Apr 18; 67(4):559-66. PubMed ID: 26321176
    [Abstract] [Full Text] [Related]

  • 20. Variability in parathyroid hormone assays confounds clinical practice in chronic kidney disease patients.
    Eddington H, Hudson JE, Oliver RL, Fraser WD, Hutchison AJ, Kalra PA.
    Ann Clin Biochem; 2014 Mar 18; 51(Pt 2):228-36. PubMed ID: 24000371
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.